摘要
目的研究肝癌病人采用经皮肝动脉化疗栓塞术(TACE)联合索拉非尼治疗的临床效果及安全性。方法肝癌病人92例,按随机数字表法分为两组,对照组46例,单纯采用TACE治疗;观察组46例,在对照组治疗基础上联合索拉非尼治疗。观察两组病人治疗效果、肝功能水平、生活质量以及不良反应。结果观察组治疗总有效率为52.17%,对照组为36.96%,两组比较差异有统计学意义(P<0.05)。治疗前两组病人总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)以及白蛋白(ALB)水平比较差异无统计学意义(P>0.05);治疗后观察组TBIL、ALT以及ALB水平低于对照组,对照组治疗后各项水平对比治疗前明显升高(P<0.05)。治疗前两组病人日常生活活动能力(ADL)评分比较无明显差异(P>0.05);治疗后观察组病人ADL评分高于对照组,差异有统计学意义(P<0.05)。观察组、对照组发生不良反应分别为24例、21例,差异无统计学意义(P>0.05)。结论经皮肝动脉化疗栓塞联合索拉非尼对肝癌病人治疗效果较好,肝功能损伤较小,不良反应发生率低。
Objective To study the efficacy and safety of transcatheter arterial chemoembolization(TACE)plus Sorafenib in hepatic carcinoma.Methods 92 hepatic carcinoma patients treated from September 2015 to June 2017 in our hospital were selected.Patients were grouped by random number table,46 cases each group.The control group was treated with TACE;the observation group was treated with TACE plus Sorafenib.The therapeutic effect,hepatic function,life quality and adverse reactions were probed.Results The total effective rate in the observation group(52.17%)was significantly higher than control group(36.96%)(P<0.05);before treatment,the index of TBIL(total bilirubin),ALT(alanine aminotransferase)and ALB(albumin)showed no statistical differences(P>0.05);after treatment,the values of TBIL,ALT and ALB in the observation group were lower than control group;the related index in the control group were significantly higher than before(P<0.05);before treatment,the ADL(activity of daily living)scores showed no statistical differences(P>0.05);after treatment,the ADL scores in the observation group were higher than control group(P<0.05);the adverse event rate in the observation group(24 cases)and control group(21 cases)showed no statistical differences(P>0.05).Conclusion The TACE plus Sorafenib can increase the therapeutic effect,reduce the hepatic injury,improve the life quality and decrease the adverse event rate.The safe and reliable therapy is worthy of clinical application and promotion.
作者
严峻
柏淳
李锋
傅文喜
余小红
YAN Jun;BO Chun;LI Feng(Department of Oncology,Huangshi Love&Health Hospital,Huangshi 435000,China)
出处
《临床外科杂志》
2019年第8期668-670,共3页
Journal of Clinical Surgery
基金
2017年度湖北省卫生计委指导性资助项目(WJ2017F052)
关键词
索拉非尼
肝癌
经皮肝动脉化疗栓塞术
安全性
Sorafenib
hepatic carcinoma
percutaneous hepatic artery chemoembolization
safety
